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The regulatory repertoire of the enteroendocrine L cell is now supplemented by Cox et al. (2010) with a two-
way paracrine loop to the neighboring enterocytes. A picture of a close local interplay in the intestine between
lipid and peptide messenger systems, both exploiting paracrine, endocrine, and neuronal pathways, is
emerging.The enteroendocrine cells and, in partic-
ular, the L cell have attracted increasing
attention as a likely origin of a major part
of the curative effect of bariatric surgery
on type 2 diabetes and obesity. Much
focus has been on the GLP-1 peptide
hormone, with its array of beneficial
effects currently being exploited in the
treatment of type 2 diabetes (Holst et al.,
2009). It has, however, been suggested
that it should be possible instead to use
compounds that control the release of
the endogenous hormones (Engelstoft
et al., 2008). This could have advantages,
such as the potential to release a true
physiological mixture of gut peptides
and to use compounds that may not enter
the body as such, but act through apical
chemosensors on the cells. However,
little is known about the control and
detailed function of enteroendocrine cells,
although the recent success in genetic
tagging and isolation of, for example,
L cells will undoubtedly change that
(Reimann et al., 2008).
In this issue, Cox and coworkers study L
cells in the isolated, intact intestinal
mucosa and focus on another of its major
peptideproducts,PYY, todescribeanovel
paracrine regulatory loop with the neigh-
boring enterocytes (Cox et al., 2010). By
use of an array of genetic and pharmaco-
logical tools, they dissect how stimulation
of the GPR119 receptor on the L cell
controls electrolyte secretion—monitored
byelectrophysiology—through the release
ofPYYactingonY1 receptors on the enter-
ocytes. Cox and coworkers use a small
synthetic compound as a GPR119 agonist
tool, which provides a high degree of
selectivity. However, the currently favored
endogenous agonist for GPR119 is oleoy-
lethanolamide (OEA) (Overton et al., 2006),
which is most likely produced mainly bythe enterocytes. Consequently, we are
faced with a novel, local regulatory mech-
anism composed of a two-way paracrine
loop: OEA generated from the enterocytes
acting through GPR119 on the neighbor-
ing L cells to regulate the release of
PYY, which controls electrolyte secretion
through the Y1 receptor back on the enter-
ocytes (Figure 1).
Importantly, the synthesis of N-acyle-
thanolamines (NAEs) such as OEA and
their biosynthetic phospholipid precur-
sors, N-acylphosphatidylethanolamines
(NAPEs), is regulated in the intestinal
mucosa by the fat content of the diet
(Hansen and Diep, 2009) (Figure 1).
In contrast to the peptide hormones,
these lipid messengers are not stored to
be released upon stimulation, but their
levels are instead continuously regulated
through enzymatic synthesis and degra-
dation (Hansen and Diep, 2009). OEA,
which is rapidly degraded in the tissue
and is therefore found only in very low
concentrations in plasma, has been
described to function as an efficacious
anorectic agent, conceivably acting
mainly through stimulation of afferent
neuronal pathways (Rodrı´guez de Fon-
seca et al., 2001). Interestingly, NAPEs
are not only biosynthetic precursors for
NAEs. They also act as anorectic factors,
but—importantly—not through a para-
crine but instead through an endocrine
mechanism targeting a still elusive re-
ceptor conceivably located in the hypo-
thalamus (Gillum et al., 2008).
The peptide hormones GLP-1 and
PYY are both well-established anorectic
agents released from the L cell not only
by fat—which is the case for NAPE (Gillum
et al., 2008)—but also by other food
components, such as protein and carbo-
hydrates. Activation of the L cell providesCell Metabolisma glucose-dependent peptide ‘‘package
solution’’ that regulates not only food
intake, but a multitude of physiological
functions, including glucose homeostasis
and, as now described, electrolyte secre-
tion from enterocytes (Cox et al., 2010).
GLP-1 and PYYboth act through a combi-
nation of endocrine and paracrine path-
ways (Figure 1). Due to the rather efficient
degradation by dipeptidylpeptidase
(DPP)-IV, a major part of the function of
GLP-1 is believed to occur through para-
crine pathways, such as activation of
afferent sensory neurons (Holst et al.,
2009). PYY is also a substrate for DPP-
IV, which, however, does not inactivate
this hormone. Instead, DPP-IV converts
PYY(1-36), which locally is a combined
Y1 and Y2 agonist, into PYY(3-36), which
selectively targets the Y2 receptor both
on local afferent nerves and on remote
targets such as the brainstem and hypo-
thalamus (Figure 1).
Thus, in the lower small intestine, the fat
content of the food regulates two
anorectic mechanisms: one being medi-
cated by lipid messengers NAPE and
NAE, and the other being mediated
through peptide messengers PYY and
GLP-1. Both anorectic mechanisms have
paracrine as well as endocrine compo-
nents, and they appear to be intercon-
nected through the local paracrine action
of OEA on the GPR119 receptor (Fig-
ure 1). Nevertheless, although GPR119 is
required for OEA to affect peptide secre-
tion from the L cell in general, this receptor
is, in contrast to the nuclear PPARa
receptor, apparently not necessary for
OEA to suppress food intake (Lan et al.,
2009). However, the molecular and
cellular basis for the dependency of the
anorectic effect of OEA upon PPARa is
still unclear (Hansen and Diep, 2009).11, June 9, 2010 ª2010 Elsevier Inc. 445
Figure 1. Schematic Overview of Putative GPR119 Receptor Activation Pathways and Major Signaling Routes for the L Cell Peptides
Putative pathways leading to activation of the GPR119 receptor on the enteroendocrine L cell and the major signaling pathways for the three peptide hormones
released upon stimulation are indicated. Between gray enterocytes is shown an L cell in green, with its microvillus-decorated apical pole reaching the gut lumen
and with peptide hormone-filled secretory granules at the base. At the top are the three main food components that stimulate L cell secretion directly through
various 7TM chemosensors (Engelstoft et al., 2008). Fat content of the food also regulates the synthesis of lipid messengers in the enterocytes, i.e., N-acylphos-
phatidylethanolamines (NAPEs), which have endocrine properties and are precursors for N-acylethanolamines (NAEs), of which oleoylethanolamide (OEA) is
believed to be a paracrine agonist for the Gs-coupled GPR119 on the L cells. Shown below are the main endocrine (red arrows), paracrine (black arrows),
and paracrine/neuronal pathways (black arrows) through which GLP-1, GLP-2, and PYY act. In the enterocyte to the right is indicated the activation by PYY
of the Gi-coupled Y1 receptor, which has an antisecretory effect on the lumenal electrolyte secretion, as determined by Cox and coworkers in this issue of
Cell Metabolism (Cox et al., 2010). The local inactivation of GLP-1 and GLP-2 and the conversion of PYY to the Y2-selective PYY(3-36) by dipeptidylpepti-
dase-IV (DPP-IV) are also indicated.
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PreviewsThe experimental approach of Cox and
coworkers using mucosal preparations
placed in Ussing chambers is particularly
suited for studying the highly polarized
enteroendocrine cells in their natural
environment. It has, for example, been a
major question whether 7TM chemosen-
sors, which are expressed both apically
and basolaterally, could be efficiently
addressed by drugs at the relatively small
apical membrane (Engelstoft et al., 2008).
This question is now positively answered
for GPR119, as small molecule agonists
are equally efficient in activating the
PYY-mediated paracrine loop whether
administered either apically or basolater-
ally (Cox et al., 2010). This is great news446 Cell Metabolism 11, June 9, 2010 ª2010for future drug discovery efforts targeting
chemosensors on enteroendocrine cells
in general, because human tissues can
easily be studied by the methods of Cox
and coworkers.
However, to obtain a picture of the ‘‘full
package,’’ we also need to get the third
major L cell product, GLP-2, into the
equation. Every time it is reported that
GLP-1 or PYY are released from L cells
by some agent, GLP-2 follows along,
although it is basically never measured
or considered. These three peptides are
all costored in secretory granules and
thereby coreleased upon stimulation (Fig-
ure 1). Besides endocrine and potential
neuronal actions, GLP-2, like the twoElsevier Inc.other peptides, also has important local
paracrine functions, as it controls the
replenishment of mucosal cells through
the release of growth factors from sub-
epithelial myofibroblasts (Ørskov et al.,
2005).
GPR119 agonists are currently in clin-
ical trials for type 2 diabetes (Jones
et al., 2009). Thus, we will soon know
whether it will be possible through this
target to reap the potential benefit of
releasing the ‘‘full package’’ of peptide
hormones from the L cell, while at the
same time stimulating insulin secretion
directly from the b cells, where GPR119
also is expressed, or whether the expres-
sion of GPR119, for example, on other
Cell Metabolism
Previewspancreatic islet cells and on other enter-
oendocrine cells may complicate the
picture.
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Adiponectin and its receptors, AdipoR1 and AdipoR2, regulate glucose and fatty acid metabolism via activa-
tion of AMP-activated protein kinase. Recent work inNature (Iwabu et al., 2010) demonstrates that adiponec-
tin induces a marked Ca2+ influx in skeletal muscle via AdipoR1 to control mitochondrial biogenesis, reduce
oxidative stress, and enhance endurance capacity.The term adipokine was coined to
describe signaling messengers that are
secreted from adipocytes, of which the
two most abundant are leptin and adipo-
nectin. Because adiponectin levels are
decreased in human obesity and type 2
diabetes, this adipokine has generated
enormous interest within the scientific
community. It has previously been shown
that adiponectin-deficient mice exhibited
insulin resistance (Maeda et al., 2002)
and that exogenous administration of
adiponectin lowered circulating glucose
and ameliorated insulin resistance (Berg
et al., 2001; Fruebis et al., 2001) via a
process thought to involve activation of
AMP-activated protein kinase (AMPK).
Recent work published in Nature (Iwabu
et al., 2010) now identifies a novel mecha-
nism by which adiponectin protects
against skeletal muscle insulin resistance
(Figure 1).
In 2003, Kadowaki and colleagues
reported the cloning of complementary
DNAs encoding adiponectin receptors 1
and 2 (Adipor1 and Adipor2) (Yamauchiet al., 2003). They found that AdipoR1 is
abundantly expressed in skeletal muscle
and liver, whereas AdipoR2 is predomi-
nantly expressed in the liver. Intriguingly,
both receptors were predicted to con-
tain seven-transmembrane domains but
were unlike G protein coupled in struc-
ture. Nonetheless, these novel receptors
maintained functionality because subse-
quent studies identified that disruption of
the adiponectin receptors AdipoR1 and
AdipoR2 abrogated adiponectin’s meta-
bolic actions (Yamauchi et al., 2007).
As insulin resistance has been linked to
mitochondrial dysfunction, many strate-
gies have been employed to improve
mitochondria function (e.g., upregulate
fatty acid oxidation rates, increase fatty
acid uptake, etc.) or increase mitochon-
dria number (mitochondrial biogenesis).
AMPK is activated when the energy
charge of the cell is low, such as during
fasting or following exercise. AMPK is
well known to stimulate an increase in
fatty acid oxidation via phosphorylation
of acetyl-CoA-carboxylase (ACC) andto upregulate mitochondrial biogenesis
through the master regulator peroxisome
proliferator-activated receptorg coactiva-
tor-1a (PGC-1a) (Ja¨ger et al., 2007). The
metabolic effects of AMPK and adiponec-
tin are similar in insulin-sensitive tissues,
and it was no surprise that, indeed, adipo-
nectin was found to regulate glucose utili-
zation and fatty acid combustion through
AMPK (Yamauchi et al., 2002). Another
cellular energy sensor, the nicotinamide
adenine dinucleotide (NAD+)-dependent
histone deacetylase silent information
regulator of transcription (SIRT1), is also
able to activate PGC-1a by deacetylation
(Lagouge et al., 2006). Because SIRT1 is
able to activate an upstream activating
AMPK kinase, LKB1, strong links between
AMPK,SIRT1, PGC-1a, and consequently
mitochondrial biogenesis and function are
emerging.
The recent study published in Nature
(Iwabu et al., 2010) has added to our
understanding of themechanismof action
of adiponectin and adipoR1 in skeletal
muscle. These authors provide detailed11, June 9, 2010 ª2010 Elsevier Inc. 447
